Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Q1 FY23 Earnings Presentation
27 slides from Genetic Technologies's earnings presentation, Nov 4, 2022
Slide 1: ASX Market Announcement: Q1 FY23 Investor Webinar Details
ASX Market Announcement For personal use only Q1 FY23 Investor Webinar Details on 4 November 2022 Genetic Technologies (ASX:GTG, NASDAQ:GENE), a global leader in guideline driven Genomics based tests in health, wellness and serious disease will be sharing the attached presentation at an investor web
Slide 2: About Genetic Technologies Limited
For personal use only About Genetic Technologies Limited Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) was founded in 1989. A global leader in guideline driven genomics- based tests in health, wellness and serious disease through its geneType and EasyDNA brands. In addition to our patented G
Slide 3: Genetic Technologies Q1 FY23 Investor Webinar
For personal use only Genetic Technologies Q1 FY23 Investor Webinar November 4, 2022 Authorised by the Board of Directors of Genetic Technologies Limited ASX: GTG NASDAQ: GENE
Slide 4: Notice: Forward looking statements
For personal use only Notice: Forward looking statements The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited (the Company) ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they
Slide 5: Unlocking personalised preventative medicine
Unlocking personalised For personal use only preventative medicine Transforming the conversation from a one-size-fits-all model to personalised, preventive health Identify risk of serious disease before onset beyond family history. Where each person has the information, they need to manage their hea
Slide 6: World leading portfolio
World leading portfolio For personal use only Most comprehensive guideline driven portfolio for human and animal health. • Patented GeneType Multi Risk Test • Non-Invasive Prenatal Testing (NIPT) • Carrier screen testing • Pharmacogenomics • Oncogenetic diseases • Pet care Revenues anchored by our 3
Slide 7: Patented Genetype tests
Patented* Genetype tests For personal use only Integrate polygenic risk and clinical risks for critical medical conditions Genetype tests integrate individual’s familial, clinical and genetic information to actionable clinical insights. A non-invasive saliva based test combines genetic and clinical
Slide 8: Global Overview
Global Overview For personal use only 57 40 25 Employees Countries Patents globally Granted* (9 Pending Worldwide*) 14 51 12 Test Tests Partner Categories Laboratories 6 * Patents granted are specific to the GeneType portfolio of products
Slide 9: Delivering Revenue and Growth – Q1 FY23
Delivering Revenue and Growth – Q1 FY23 For personal use only Cash Receipts (A$'000) $6,789 Q1 CASH RECEIPTS CASH BALANCE 145% A$2.06m A$7.9m* Growth half-year ending December on LY 31, 2021 $2,060 GROSS MARGIN GROSS MARGIN $89 Full Year FY21 Full Year FY22 $850 Q1 FY22 Q1 FY23 A$0.9m 44% Strategic
Slide 10: Execute the B2B commercialisation of the geneType multi-risk test
For personal use only Execute the B2B commercialisation of the geneType multi-risk test Commercialisation of the geneType suite of multi-risk tests Commercialisation of the geneType suite of multi-risk tests Demonstrate clinical validity & clinical utility of geneType tests Our FOCUS Core ‘4’ EasyDN
Slide 11: Our Innovation – Multi-Risk Test
Our Innovation – Multi-Risk Test GeneType can identify patients ’at risk’ before onset and aid in the early detection and treatment. For personal use only GeneType Risk assessment test for breast cancer has demonstrated improved early stage detection by 18% and saving approx. US$1.4B per annum4 for
Slide 12: Economic Modeling in the US Payer System
Economic Modeling in the US Payer System1 The economic benefit to the payers in the US is US$1.4B per annum For personal use only $73 69% - 74% 6.8%-9.2% US Payor system overall increase in Supplemental will save per women getting screening frequency patient per year screened 14.8% - 8.8% 57% - 67%
Slide 13: GeneType Identifies More Cancer Risk Patients Compared to Existing SoC Models
GeneType Identifies up to 9 Times More Cancer Risk Patients Compared to Existing SoC Models1 For personal use only The paper, titled “Integrating Personalised Medicine into Preventative Care through Risk Stratification” Published in the Journal of Precision Medicine 1 https://www.thejournalofprecisi
Slide 14: Divisions of Operations
Divisions of Operations For personal use only NEW Existing divisions Universal Pharmoco- collection test kit Oncology Genetics & Emerging divisions BC, CRC, PC, Taliaz to support Multi Melanoma Companion Test Launch diagnostics Germline CVD testing (Heart Disease) BRCA, Lynch IHD, AF Syndrome and So
Slide 15: Pathways to Market
Pathways to Market Executing a multi-brand strategy For personal use only Consumer initiated Direct to Consumer Medical & Payer Testing (DTC) testing (CIT) Business to with no medical supervision Business (B2B) with medical supervision Oncology – GTG Expanded Carrier testing & NIPT [insert revenue s
Slide 16: Pathways to Market – highest priority
Pathways to Market – highest priority For personal use only Payer coverage is the key driver of revenues for geneType Medical & Payer Coverage from payers in the US will accelerate adoption of geneType Risk Business to Assessment Tests more widely Business (B2B) Budget Impact Model (BIM) demonstrate
Slide 17: Collaborations
Collaborations For personal use only Professor Bernard Professor Graham Professor John Rosner Colditz Hopper Channing Division of Network Medicine, Deputy Director, Institute for Public Professorial Fellow at the Centre for Brigham and Women’s Hospital and Health. Washington University School Epidem
Slide 18: Collaborations
Collaborations For personal use only Professor Jon Memorial Sloane Ohio State Emery Kettering Cancer University Professor of Primary Care Cancer Collaborating on a project to Collaborating on a project to Research at the University of investigate modification of risk in BRCA- investigate modificatio
Slide 19: DTC - Growth strategy for EasyDNA
DTC - Growth strategy for EasyDNA For personal use only PHASE 1 PHASE 2 Brand Re-Ignition Revenue and Growth Focus [insert revenue structure and [insert revenue structure and agreement types] Brand Refreshagreement Website types] Refresh Improved Lead Gen New Sales Channels Product list Product list
Slide 20: Thank you
For personal use only Thank you Investor Relations Adrian Mulcahy Market Eye – Automic Group www.linkedin.com/company/genetype-limited M: +61 438 630 422 E: adrian.mulcahy@automicgroup.com.au www.genetype.com 19
Slide 21: Appendices
For personal use only Appendices 20
Slide 22: Corporate Overview
Corporate Overview For personal use only Top 50 share registry breakdown BNY Mellon Board & Management Other Dual Listed on the ASX and Nasdaq Financial Information Share price (AUD) as at 25 October 2022 0.3c Other, 25% ADR price (USD) as at 25 October 2022 $1.20 Ord Shares on Issue (M) 9,234 ASX 5
Slide 23: Financial Overview
Financial Overview For personal use only • Net cash outflow of A$3.4 million in Q1 FY’23 (compared to Q4 FY’22 inflow of: A$197k) as we continue to grow EasyDNA and Affinity DNA brand sales and develop and commercialize our geneType tests A$’000 30-Sep-22 30-Jun-22 Change • Cash reserves of A$7.9 mi
Slide 24: Board and Management
Board and Management: Sales and Scientific expertise leading GTG For personal use only Mr. Peter Rubinstein Dr. Lindsay Wakefield Mr Nick Burrows BEc, LLB MBBS B.Com, FAICD, FCA, Chairman - Non – Non – Executive FGIA, FTIA, F Fin Executive Director Director Non – Executive Director Dr. Jerzy “George
Slide 25: Strong Scientific Leadership: Advisory Board
Strong Scientific Leadership: Advisory Board For personal use only Professor Jon Emery Professor Finlay Macrae AO Ora K. Gordon, M.D. A.Prof Ron Dick MBBCh MA DPhil FRACGP MRCGP MBBS, MD, FRACP, FRCP, AGAF MD, MS, FACMG MBBS, FRACP, FCSANZ, Research & Education Lead, MWGO is Principal Fellow and Reg
Slide 26: Our Intellectual Property
Our Intellectual Property For personal use only 4 Patents granted in the US 9 Patent families pending • Patent No: US 11,257,569, Methods of • Breast cancer risk assessment assessing risk of developing a severe • Methods for assessing risk of developing prostate cancer response to Coronavirus infect
Slide 27: Defined Terms
Defined Terms For personal use only Common Complex Diseases (CCP) – A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease. Polygenic risk score